Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of multiple myeloma by blocking blood flow to the cancer. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with relapsed or refractory multiple myeloma.

Timeline

Start

2006-04

Primary completion

2006-12

Completion

2009-11

Drugs

Indications